Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection

Journal of Infectious Diseases

Volumn 210, Issue 3, 2014, Pages 448-455

  Wilson, Lauren ^a,d   Pawlita, Michael ^e   Castle, Phillip E ^b   Waterboer, Tim ^e   Sahasrabuddhe, Vikrant ^a   Gravitt, Patti E ^c   Schiffman, Mark ^a   Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Global Cancer Initiative   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Human papillomavirus; Natural immunity; Serology

Indexed keywords

VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; DISEASE ASSOCIATION; DNA TUMOR VIRUS; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; INFECTION RISK; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REINFECTION; RISK ASSESSMENT; SEROLOGY; SEROPREVALENCE; UTERINE CERVIX CARCINOMA IN SITU;

HUMAN PAPILLOMAVIRUS; NATURAL IMMUNITY; SEROLOGY;

ADAPTIVE IMMUNITY; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENOTYPE; HUMANS; ODDS RATIO; ONCOGENIC VIRUSES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEROEPIDEMIOLOGIC STUDIES;

EID: 84898596632     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu104     Document Type: Article

References (40)

1. Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
2. Muñoz N, Méndez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077-87.
3. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831-6.
4. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008; 9:425-34.
5. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection. Cancer Epidemiol Biomarkers Prev 2004; 13:324-7.
6. Wang SS, Schiffman M, Herrero R, et al. Determinants of human papillomavirus 16 serological conversion and persistence in a populationbased cohort of 10,000 women in Costa Rica. Br J Cancer 2004; 91:1269-74.
7. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928-43.
8. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271-8.
9. Quadrivalent vaccine against human papillomavirus to prevent highgrade cervical lesions. N Engl J Med 2007; 356:1915-27.
10. Opalka D, Matys K, Bojczuk P, et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 2010; 17:818-27.
11. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem 2005; 51:1845-53.
12. Michael KM, Waterboer T, Sehr P, et al. Seroprevalence of 34 human papillomavirus types in the german general population. PLoS Pathog 2008; 4:e1000091.
13. Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol 2000; 44: 726-42.
14. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse Line Blot detection method. J Clin Microbiol 1998; 36:3020-7.
15. Wentzensen N, Gravitt PE, Solomon D, Wheeler CM, Castle PE. A study of Amplicor human papillomavirus DNA detection in the Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study. Cancer Epidemiol Biomarkers Prev 2009; 18:1341-9.
16. Castle PE, Schiffman M, Gravitt PE, et al. Comparisons of HPV DNA detection by MY09//11 PCR methods. J Med Virol 2002; 68: 417-23.
17. Schiffman M, Wheeler CM, Dasgupta A, Solomon D, Castle PE, ALTS Group. A comparison of a prototype PCR assay and Hybrid Capture 2 for detection of carcinogenic human papillomavirus DNA in women with equivocal or mildly abnormal Papanicolaou Smears. Am J Clin Pathol 2005; 124:722-32.
18. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. Comparison of Linear Array and Line Blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study. J Clin Microbiol 2008; 46:109-17.
19. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38:357-61.
20. Sehr P, Müller M, Höpfl R, Widschwendter A, Pawlita M. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 2002; 106:61-70.
21. Clifford G, Shin H, Oh J, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007; 16:1874-9.
22. Insinga RP, Perez G, Wheeler CM, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomarkers Prev 2011; 20: 287-96.
23. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM, ALTS Group. 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of Atypical Squamous Cells of Undetermined Significance or Low-Grade Squamous Intraepithelial Lesion. J Infect Dis 2007; 195:1582-9.
24. Wentzensen N, Rodriguez AC, Viscidi R, et al. A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis 2011; 204:94-102.
25. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and-18 infections. J Natl Cancer Inst 2010; 102:1653-62.
26. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186:737-42.
27. Malik ZA, Hailpern SM, Burk RD. Persistent antibodies to HPV viruslike particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol 2009; 22:445-9.
28. Trottier H, Ferreira S, Thomann P, et al. Human papillomavirus infection and reinfection in adult women: the role of sexual activity and natural immunity. Cancer Res 2010; 70:8569-77.
29. Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A. Prevalence and incidence of HPV genital infection in women. Sex Transm Dis 2009; 36:696-703.
30. Wilson LE, Pawlita M, Castle PE, et al. Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study. Int J Cancer 2013; 133:2172-81.
31. Gravitt PE. The known unknowns of HPV natural history. J Clin Invest 2011; 121:4593-9.
32. Gravitt PE, Rositch AF, Silver MI, et al. A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States. J Infect Dis 2013; 207:272-80.
33. Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 2012; 72:6183-90.
34. Insinga RP, Perez G, Wheeler CM, et al. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev 2010; 19: 1585-94.
35. Kelly RS, Walker P, Kitchener H, Moss SM. Incidence of cervical intraepithelial neoplasia grade 2 or worse in colposcopy-negative/human papillomavirus-positive women with low-grade cytological abnormalities. BJOG 2012; 119:20-5.
36. Pretorius RG, Zhang W-H, Belinson JL, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol 2004; 191:430-4.
37. Gage JC, Hanson VW, Abbey K, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006; 108:264-72.
38. Castle PE, Gravitt PE, Wentzensen N, Schiffman M. A descriptive analysis of prevalent vs incident cervical intraepithelial neoplasia grade 3 following minor cytologic abnormalities. Am J Clin Pathol 2012; 138:241-6.
39. Kemp TJ, García-Piñeres A, Falk RT, et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008; 26:3608-16.
40. Rizk RZ, Christensen ND, Michael KM, et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 2008; 89:117-29.